Biotech RadarJobs updated

COMPANY

Tern Therapeutics

HQ: Washington, DC source · terntx.com ↗

Clinical Phase 2

Keywords: gene therapy blindness neuronal ceroid lipofuscinosis 2 neurology Neuronal Ceroid Lipofuscinosis Type 2 TTX-381

Location: Washington, DC · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Timeline

  1. Trial start Phase 1/Phase 2: A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid source ↗

Clinical trials (lead sponsor) 1

RecordTitlePhaseStatusStartPrimary completion
NCT05791864A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) DiseasePhase 1/Phase 2RecruitingMay 17, 2023Jul 30, 2026 (estimated)
Feedback